Results 51 to 60 of about 31,828 (224)

TMPRSS2-ERG gene fusion in prostate cancer [PDF]

open access: yesBiomedical Papers, 2014
The TMPRSS2-ERG gene fusion is one of the most widely spread chromosomal rearrangements in carcinomas. Since its discovery, a number of studies have examined its diagnostic, prognostic and therapeutic implications for prostate cancer where suitable biomarkers are still lacking. The publication data are inconsistent.
Alena, Burdova   +3 more
openaire   +2 more sources

In Silico Study on Spice-Derived Antiviral Phytochemicals Against SARS-CoV-2 TMPRSS2 Target

open access: yes, 2020
We predicted the structure of TMPRSS2 (transmembrane protease serine 2), a host protein that truncates spike protein of SARS-CoV-2. Then we docked 18 anti-viral compounds found in Indian spices against the catalytic domain of TMPRSS2.
Amit, Jaiswal   +2 more
core   +1 more source

ACE2 and TMPRSS2 partially overlap.

open access: yes, 2022
Autofluorescence in grey (488 channel), co-staining in red (647 channel), and purple (730 channel), with overlapping regions in pink (colorblind-proof).
Kim M. Bouwman (4112605)   +13 more
core   +1 more source

Evidence of SARS-CoV-2 Transmission Through the Ocular Route

open access: yesClinical Ophthalmology, 2021
Jing-Yu Qu, Hua-Tao Xie, Ming-Chang Zhang Department of Ophthalmology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, People’s Republic of ChinaCorrespondence: Ming-Chang Zhang; Hua-Tao ...
Qu JY, Xie HT, Zhang MC
doaj  

ACE-2, TMPRSS2 and Beyond; Promising Targets and Tools for COVID-19 Prophylaxis and Treatment

open access: yesBezmiâlem Science, 2020
Several repurposing drugs and ongoing vaccine researches to combat Coronavirus Disease-19 (COVID-19) are testing clinically, worldwide. COVID-19 caused by severe acute respiratory failure syndrome-CoV-2, uses angiotensin-converting enzyme 2 (ACE-2) as a ...
Akçahan GEPDİREMEN, Meltem KUMAŞ
doaj   +1 more source

Ginsenosides, potential TMPRSS2 inhibitors, a trade-off between the therapeutic combination for anti-PD-1 immunotherapy and the treatment of COVID-19 infection of LUAD patients

open access: yesFrontiers in Pharmacology, 2023
Background: Acting as a viral entry for coronavirus to invade human cells, TMPRSS2 has become a target for the prevention and treatment of COVID-19 infection.
Mei Meng   +8 more
doaj   +1 more source

TMPRSS2 Is an Activating Protease for Respiratory Parainfluenza Viruses [PDF]

open access: yesJournal of Virology, 2013
ABSTRACT Here, we show that human parainfluenza viruses and Sendai virus (SeV), like other respiratory viruses, use TMPRSS2 for their activation. The membrane fusion proteins of respiratory viruses often possess serine and glutamine residues at the P2 and P3 positions, respectively, but these residues were not critical for cleavage by TMPRSS2.
Masako, Abe   +16 more
openaire   +2 more sources

TMPRSS2 and COVID-19: Serendipity or Opportunity for Intervention? [PDF]

open access: yesCancer Discovery, 2020
Abstract TMPRSS2 is both the most frequently altered gene in primary prostate cancer and a critical factor enabling cellular infection by coronaviruses, including SARS-CoV-2. The modulation of its expression by sex steroids could contribute to the male predominance of severe infections, and given that TMPRSS2 has no known indispensable ...
Konrad H. Stopsack   +4 more
openaire   +2 more sources

Virtual Drug Repurposing Study Against SARS-CoV-2 TMPRSS2 Target

open access: yes, 2020
Currently, the world suffers from a new coronavirus SARS-CoV-2 that causes COVID-19. Therefore, there is a need for the urgent development of novel drugs and vaccines for COVID-19.
Serdar, Durdagi
core   +1 more source

Downregulation of TMPRSS2 mRNA with 48 h stimulated myokine treatment.

open access: yes, 2022
(a): TMPRSS2 qPCR in 16HBE14o. Real time pcr revealed a 41% reduction of TMPRSS2 mRNA with stimulated myokines. (b): TMPRSS2 qPCR in A549. Stimulated myokine treatment reduced TMPRSS2 gene expression by 75.7%.
Beth Parker (1792180)   +6 more
core   +1 more source

Home - About - Disclaimer - Privacy